New oral drug cocktail shows promise for kids with resistant neuroblastoma

NCT ID NCT00093353

Completed Disease control Sponsor: New Approaches to Neuroblastoma Therapy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a combination of three oral drugs (irinotecan, temozolomide, and cefixime) in 30 children whose high-risk neuroblastoma had come back or not responded to standard treatment. The goal was to find the safest dose of irinotecan when given with the other two drugs. Cefixime was included to help prevent diarrhea, a common side effect of irinotecan. The study focused on side effects and dosing, not on curing the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIARRHEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diarrheal disease Drug-Related Side Effects and Adverse Reactions neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIARRHEA DRUG/AGENT TOXICITY BY TISSUE/ORGAN NEUROBLASTOMA

Contacts and locations

Locations

AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus

Atlanta, Georgia, 30322, United States
Children's Hospital Boston

Boston, Massachusetts, 02115, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027-0700, United States
Children's Hospital and Regional Medical Center - Seattle

Seattle, Washington, 98105, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Children's Memorial Hospital - Chicago

Chicago, Illinois, 60614, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229-3039, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Indiana University Cancer Center

Indianapolis, Indiana, 46202-5289, United States
Lucile Packard Children's Hospital at Stanford University Medical Center

Palo Alto, California, 94304, United States
Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital

Houston, Texas, 77030-2399, United States
UCSF Comprehensive Cancer Center

San Francisco, California, 94143, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109-0718, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.